Navigation Links
Pharmaceutical Industry Confronting Big Challenges, Opportunities in 2012: Leaders to Convene at Groundbreaking Event on February 7-8 in New Jersey
Date:1/11/2012

PARSIPPANY, N.J., Jan. 11, 2012 /PRNewswire/ -- The year 2012 sets the stage for an exciting, yet challenging time for the pharmaceutical industry. To address what lies ahead in the New Year, the pharma industry's leading experts all plan to be at the Pharma Market Research Conference. This overwhelmingly popular event takes place on February 7-8 at the Hilton Parsippany Hotel in New Jersey.

Under the guidance of the esteemed advisory board with members from Alexion Pharmaceuticals, Bayer Healthcare, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Purdue Pharma, Shire Pharmaceuticals, Takeda Pharmaceuticals, Teva Health Systems and many more, the Pharma Market Research Conference is a prestigious event known for providing the best and latest information to all participants. This is the premier gathering of senior level pharmaceutical, biotechnology, medical device, and diagnostics executives in market research.  To view the advisory board, go to: http://www.pharmamarketresearchconference.com/advisory_board.html

Here's what one Merck executive said about the conference: "...a terrific opportunity to interact with fellow market research professionals and market research agencies in order to share best practices both for conducting market research and for how agencies and industry can most effectively interact. I came away feeling energized to try out new methodologies that I had learned about and to further familiarize myself with agencies that I met at the conference."

Time and time again, participants are overwhelmingly impressed with the Pharma Market Research Conference's outstanding program featuring an elite group of expert speakers who come from stellar companies like Abbott Laboratories, Alkermes, Allergan, Inc., Amylin Pharmaceuticals, Astellas Pharma, Auxilium Pharmaceuticals, Bayer Healthcare, Bristol-Myers Squibb, Cephalon, Covidien, Daiichi Sankyo, GE Healthcare Systems, GlaxoSmithKline, Johnson & Johnson, Lundbeck Inc., Mead Johnson, Merck, Millennium Pharmaceuticals, NPS Pharmaceuticals, Pfizer, Purdue Pharma, Roche, Shionogi Inc., Shire Pharmaceuticals, Takeda Pharmaceuticals, Teva Health, and many more! To view the detailed program agenda, go to: http://pharmamarketresearchconference.com/program

The Pharma Market Research Conference is your EXCLUSIVE ENTRY into the world of pharmaceutical market research. Nowhere else will you find the industry's best and brightest all under one roof!  More than 250 people came in 2011, and 2012 is expected to be even bigger and better.  For more information or to register, call +1.212.228.7974 or go to: http://pharmamarketresearchconference.com/

Contact:
Amy Yueh
Pharma Market Research Conference
info@pharmamarketresearchconference.com
+1.212.228.7974
www.pharmamarketresearchconference.com

 


'/>"/>
SOURCE Pharma Market Research Conference
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):